Speaker 1: Bloomberg Audio Studios, podcasts, radio News, The.
Speaker 2: Stock Movers Report, your roundup of companies making moves in
Speaker 2: the stock market, harnessing the power of Bloomberg Data. Let's
Speaker 2: take a look at some of the stocks on the
Speaker 2: move today.
Speaker 3: We can do that with Bloomberg's avalon per Now, avalon,
Speaker 3: what are you looking at today? Yeah, we can start
Speaker 3: off with Constellation Energy. That's ticker CEG sliding about eight
Speaker 3: point seven percent right now. That's after the power generation
Speaker 3: firm forecast earnings per share for the full year that
Speaker 3: missed estimates. Barclay's saying that expectations were pretty high going
Speaker 3: into the print and noting that the outlook looks sort
Speaker 3: of mixed with nuclear contracting progressing, but that EPs outlook
Speaker 3: again coming in below estimates, and that move is making
Speaker 3: Constellation Energy one of the worst performers in the S
Speaker 3: and P five hundred today.
Speaker 2: All right, let's take a look at some M and
Speaker 2: A as well.
Speaker 3: Yes, McCormick, that's ticker MKC, falling about five point four
Speaker 3: percent to hit its lowest inter day level since twenty eighteen.
Speaker 3: That's after Despises and Seasoning Maker agreed to combine with
Speaker 3: Funial lovers food business and a deal valued at about
Speaker 3: forty four point eight billion dollars. Vital Knowledge says, despite
Speaker 3: McCormick reporting decent results this morning, food focused staples are
Speaker 3: generally hated by investors given the cyclical headwinds and the
Speaker 3: industry's history when it comes to large scale m and a,
Speaker 3: so I thought that was kind of interesting.
Speaker 2: Another MNA trade A Palace Pharmaceuticals.
Speaker 3: Yes, a Palace Pharmaceuticals ticker APLS, jumping one hundred and
Speaker 3: thirty seven percent for its most inter day on record.
Speaker 3: That's after Biogen agreed to buy the biotech for about
Speaker 3: five point six billion dollars. RBC says this is a
Speaker 3: really good deal for a pelas given their shares have
Speaker 3: struggled a lot recently, and the deal will help Biogen
Speaker 3: boost its kidney franchise and expand its treatments in rare
Speaker 3: diseases and immunology.
Speaker 2: This stock mover's report from Bloomberg Radio. Check back with
Speaker 2: us throughout the day for the latest roundup of companies
Speaker 2: making news on Wall Street and for the latest market
Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
Speaker 2: the Bloomberg Business App